FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a synthetic particle for delivering a genetic element into a eukaryotic cell (embodiments), a genetic element for delivering an exogenous effector (embodiments), a pharmaceutical composition for delivering a genetic effector, a host cell for producing a synthetic particle (embodiments), use of a synthetic particle or a pharmaceutical composition for delivering a genetic element to a host cell, use of the synthetic particle or pharmaceutical composition for treating an immune disorder, interferonopathy, an infectious disease, an inflammatory disorder, an autoimmune condition or cancer in a subject, method of treating a disease or disorder in a subject, comprising administering to the subject a synthetic particle or pharmaceutical composition, where the disease or disorder is selected from an immune disorder, an interferonopathy, an inflammatory disorder, an autoimmune condition and cancer, and a method for preparing the composition based on the synthetic particle.
EFFECT: invention extends the range of means for delivering a genetic element into a eukaryotic cell.
46 cl, 22 dwg, 23 tbl, 25 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
UNIVERSAL VACCINE BASED ON COMMON TUMOR NEOANTIGENS FOR THE PREVENTION AND TREATMENT OF CANCER WITH MICROSATELLITE INSTABILITY (MSI) | 2018 |
|
RU2792843C2 |
COMPOSITIONS AND METHODS OF PRODUCING (R)-RETICULIN AND ITS PRECURSORS | 2014 |
|
RU2729065C2 |
HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES | 2016 |
|
RU2753884C2 |
METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING MALIGNANT TUMOUR | 2016 |
|
RU2718499C2 |
ANTICANCER VACCINES | 2017 |
|
RU2718663C2 |
ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
Authors
Dates
2024-07-15—Published
2018-06-13—Filed